Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOAC: Neoadjuvant and adjuvant dabrafenib + trametinib in BRAF-mutated anaplastic thyroid cancer
2024-516126-54-00Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), sponsored by Leiden University Medical Center. Primary endpoint: Rate of successful R0 tumor resection. Planned start Oct 2024; status: authorised.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on 2024-516126-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516126-54-00.